Cargando…

No benefit of chemotherapy in Osimertinib-treated postoperative non-small cell lung cancer patients

Detalles Bibliográficos
Autores principales:	Li, Feng, Zhao, Yi, Zhong, Ran, Cai, Xiuyu, Liu, Jun, He, Jianxing, Liang, Wenhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435392/ https://www.ncbi.nlm.nih.gov/pubmed/34584867 http://dx.doi.org/10.21037/tlcr-21-640

Ejemplares similares

Meningeal metastasis patients with EGFR G724S who develop resistance to osimertinib benefit from the addition of afatinib
por: Li, Yibin, et al.
Publicado: (2020)

Novel evidence revealed genetic association between COVID-19 infection, severity and endometrial cancer
por: Wu, Xiangrong, et al.
Publicado: (2022)

Gout and susceptibility and severity of COVID-19: A bidirectional Mendelian randomization analysis
por: Peng, Haoxin, et al.
Publicado: (2022)

m(6)A regulators as predictive biomarkers for chemotherapy benefit and potential therapeutic targets for overcoming chemotherapy resistance in small-cell lung cancer
por: Zhang, Zhihui, et al.
Publicado: (2021)

Personal protective equipment protecting healthcare workers in the Chinese epicentre of COVID-19
por: Zhao, Yi, et al.
Publicado: (2020)

Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA
por: Tsuboi, Masahiro, et al.
Publicado: (2021)

Effective clinical response of lung adenocarcinoma harboring EGFR 19Del/T790M/in cis-C797S osimertinib to osimertinib and gefitinib combination therapy
por: Wang, Yanyan, et al.
Publicado: (2023)

The impact of postoperative EGFR-TKIs treatment on residual GGO lesions after resection for lung cancer
por: Cheng, Bo, et al.
Publicado: (2021)

Osimertinib in Indian patients with T790M-positive advanced nonsmall cell lung cancer
por: Noronha, Vanita, et al.
Publicado: (2017)

A nomogram for predicting overall survival in patients with resected non-small cell lung cancer treated with chemotherapy
por: Zeng, Yuan, et al.
Publicado: (2021)

Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases
por: Jiang, Tao, et al.
Publicado: (2020)

Is there a role for sequential afatinib and osimertinib in patients with EGFR mutation?
por: Iwamoto, Natsuhiko, et al.
Publicado: (2022)

Sleeve lobectomy after neoadjuvant chemoimmunotherapy/chemotherapy for local advanced non-small cell lung cancer
por: Liang, Hengrui, et al.
Publicado: (2021)

Adoptive Immunotherapy in Postoperative Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Zeng, Yuan, et al.
Publicado: (2016)

Association between certain non–small cell lung cancer driver mutations and predictive markers for chemotherapy or programmed death‐ligand 1 inhibition
por: Liang, Wenhua, et al.
Publicado: (2019)

Prevalence and clinical characterization of cancer patients with asymptomatic SARS-CoV-2 infection history
por: Bi, Jianping, et al.
Publicado: (2020)

Stereotactic radiosurgery alone for small cell lung cancer: a neurocognitive benefit?
por: Ojerholm, Eric, et al.
Publicado: (2014)

Serosurvey of SARS-CoV-2 among hospital visitors in China
por: Liang, Wenhua, et al.
Publicado: (2020)

Profiling Tumor Immune Microenvironment of Non-Small Cell Lung Cancer Using Multiplex Immunofluorescence
por: Peng, Haoxin, et al.
Publicado: (2021)

Tumor‐infiltrating CD8(+) T cell is prognostic and predicts adjuvant chemotherapy benefit in patients with limited‐stage small cell esophageal carcinoma
por: Zhang, Zhihui, et al.
Publicado: (2021)

Precise Therapeutic Benefits and Underlying Mechanisms of Anlotinib Combined With Checkpoint Immunotherapy in Advanced Non-Small-Cell Lung Cancer
por: Xiang, Yi, et al.
Publicado: (2022)

Synergistic augmentation of osimertinib‐induced autophagic death by proguanil or rapamycin in bladder cancer
por: Xiao, Di, et al.
Publicado: (2023)

“Major pathologic response” in lymph nodes: a modified nodal classification for non-small cell lung cancer patients treated with neoadjuvant immunochemotherapy
por: Deng, Hongsheng, et al.
Publicado: (2023)

Correction: Potential benefit of osimertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer
por: Yi, Yali, et al.
Publicado: (2022)

Prognostic and predictive impact of creatine kinase level in non-small cell lung cancer treated with tyrosine kinase inhibitors
por: Jiang, Yu, et al.
Publicado: (2021)

Treating EGFR mutation resistance in non-small cell lung cancer – role of osimertinib
por: Mazza, Valentina, et al.
Publicado: (2017)

Epiphora following chemotherapy with pemetrexed in patients with advanced non-small cell lung cancer
por: Jung, Yun Duk, et al.
Publicado: (2017)

Non-small cell lung cancer with MET exon 14 skipping alteration responding to immunotherapy: a case report
por: Chen, Zhuxing, et al.
Publicado: (2021)

Hypofractionated chemoradiotherapy for locally advanced non-small cell lung cancer: Is split-dose chemotherapy safer than full dose chemotherapy?
por: Iqbal, Muhammad Shahid, et al.
Publicado: (2021)

The association of postoperative radiotherapy with survival in resected N2 non-small cell lung cancer
por: Zeng, Yuan, et al.
Publicado: (2023)

Aspirin and risk of different cancers: an umbrella meta-analysis
por: Jiang, Yu, et al.
Publicado: (2020)

Response to “Hypofractionated chemoradiotherapy for locally advanced non-small cell lung cancer: Is split-dose chemotherapy safer than full dose chemotherapy?”
por: Kepka, Lucyna, et al.
Publicado: (2021)

Anti‐PD1 or anti‐PD‐L1 antibodies alone or in combination with chemotherapy first‐line treatment of advanced non‐small cell lung cancer
por: Zhang, Xuexia, et al.
Publicado: (2022)

Intratumoral tertiary lymphoid structure (TLS) maturation is influenced by draining lymph nodes of lung cancer
por: He, Miao, et al.
Publicado: (2023)

Cardiac Adverse Events in EGFR-Mutated Non-Small Cell Lung Cancer Treated With Osimertinib
por: Kunimasa, Kei, et al.
Publicado: (2020)

The value of local consolidative therapy in Osimertinib-treated non-small cell lung cancer with oligo-residual disease
por: Zeng, Ya, et al.
Publicado: (2020)

Immunomodulatory effects of chemotherapy on blood lymphocytes and survival of patients with advanced non-small cell lung cancer
por: Aldarouish, Mohanad, et al.
Publicado: (2019)

Smoking cessation before initiation of chemotherapy in metastatic non-small cell lung cancer: influence on prognosis
por: Linhas, Ana Rita Diegues, et al.
Publicado: (2018)

Immunotherapy plus chemotherapy showed superior clinical benefit to chemotherapy alone in advanced NSCLC patients after progression on osimertinib
por: Long, Yaping, et al.
Publicado: (2021)

Clinical characteristics and outcomes of Chinese patients with KRAS‐mutant non‐small cell lung cancer after chemotherapy
por: Zheng, Yawen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_llr5h7cm0o2rsu9s2ff24d1b5e